Diabetes

Company Drug

NMPA Accepts Hengrui’s New Drug Application for Ribupatide Injection – Dual GLP‑1/GIP Receptor Agonist Nears Approval for Type 2 Diabetes in China

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that the New Drug Application...

Company Drug

GanLee’s GZC8072 Wins NMPA IND Approval for Once‑Weekly Oral Type 2 Diabetes Candidate

Fineline Cube Sep 4, 2026

Gan & Lee Pharmaceuticals (SHA: 603087) announced that its drug candidate GZC8072 has received Investigational...

Company Drug

Hengrui Pharmaceuticals’ Oral GLP‑1R Agonist HRS‑7535 NDA Accepted by NMPA for Type 2 Diabetes, Joining China’s Incretin Race

Fineline Cube Sep 3, 2026

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that its New Drug Application...

Company Drug

Hengrui Pharmaceuticals Wins NMPA Clearance for Phase II Trial of HRS‑4729, a Triple‑Agonist Peptide Drug for Type 2 Diabetes

Fineline Cube Aug 17, 2026

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that its drug HRS‑4729 has...

Company Legal / IP

Novo Nordisk Sues Eli Lilly Over Alleged False Advertising of Zepbound and Mounjaro in GLP-1 Market

Fineline Cube Jul 22, 2026

Novo Nordisk A/S (NYSE: NVO) announced it has filed a lawsuit against Eli Lilly and...

Company Drug

Mabwell Bioscience Secures NMPA Approval for 9MW5211 Antibody in Type 1 Diabetes, Expanding Autoimmune Pipeline

Fineline Cube Jul 8, 2026

Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062, HKG: 2493) announced that its clinical trial application...

Company Drug

Hybio Pharma’s Generic Tirzepatide ANDA Accepted by FDA – First-to-File Challenger Targets $20B+ Dual GLP-1/GIP Agonist Franchise with Paragraph IV Certification

Fineline Cube Jul 1, 2026

Shenzhen Hybio Pharmaceutical Co., Ltd. (SHE: 300199) announced today that the U.S. Food and Drug...

Company Drug

Hua Medicine Completes Greater China Rollout as Dorzagliatin Gains Macau Approval – First-in-Class Glucokinase Activator Now Available Across All Chinese Territories

Fineline Cube Jun 30, 2026

Hua Medicine (HKG: 2552) announced that the Pharmaceutical Administration Bureau of the Macau Special Administrative...

Company Deals Drug

MacroGenics Secures $24.5M Milestone from Sanofi Following FDA Approval Expansion for Tzield in Type 1 Diabetes

Fineline Cube Jun 23, 2026

MacroGenics, Inc. (NASDAQ: MGNX) announced it will receive a USD 24.5 million regulatory milestone payment...

Company Drug

Gan & Lee Pharmaceuticals Secures UAE Approval for Insulin Glargine Prefilled Pen, Expanding Global Diabetes Portfolio

Fineline Cube Jun 22, 2026

Gan & Lee Pharmaceuticals (SHA: 603087) announced that the Ministry of Health and Prevention (MOHAP)...

Company Drug

CSPC Pharmaceutical’s Efmedaglutide Alfa GLP-1 Therapy Accepted for NMPA Review in Type 2 Diabetes Indication

Fineline Cube Jun 22, 2026

CSPC Pharmaceutical Group Limited (HKG: 1093) announced that China’s National Medical Products Administration (NMPA) has...

Company Drug

Sanofi’s Tzield Receives FDA Approval to Preserve Insulin Production in Recently Diagnosed Type 1 Diabetes

Fineline Cube Jun 15, 2026

Sanofi (NASDAQ: SNY) announced that the U.S. Food and Drug Administration (FDA) has granted accelerated...

Company Deals

PegBio Receives $7.8M Milestone Payment from Tenry Pharma for Paidakang GLP-1 Agonist – Chinese Biotech Secures First Commercial Revenue from Type 2 Diabetes Asset

Fineline Cube Jun 8, 2026

PegBio Co., Ltd. (HKG: 2565) announced receipt of the first milestone payment of HKD 61...

Company Drug

Novo Nordisk’s CagriSema Fixed-Dose Combination Delivers Superior HbA1c and Weight Loss in Phase 3 REIMAGINE Trials – Amylin/GLP-1 Dual Therapy Outperforms Semaglutide Monotherapy

Fineline Cube Jun 8, 2026

Novo Nordisk A/S (NYSE: NVO) presented comprehensive Phase 3 results from the REIMAGINE 1-3 clinical...

Company Deals

Shandong Boan Biotech Licenses BA5101 Dulaglutide Biosimilar for US Market – First Global Copycat of Trulicity

Fineline Cube Jun 4, 2026

Shandong Boan Biotechnology Co., Ltd. (HKG: 6955) announced a licensing agreement with an undisclosed pharmaceutical...

Company Deals

Hanmi Pharm Secures $1.26 Billion Deal with Eli Lilly for GLP-2 Analog Sonefpeglutide in Global Licensing Agreement

Fineline Cube Jun 1, 2026

Hanmi Pharm. Co., Ltd. (“Hanmi”) announced a strategic global licensing agreement with Eli Lilly (NYSE:...

Company Drug

Hengrui Pharmaceuticals and Kailera Therapeutics Report Strong Phase III Results for Oral GLP-1 Agonist HRS-7535 in Type 2 Diabetes

Fineline Cube May 27, 2026

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) and its U.S. partner Kailera Therapeutics...

Company Drug

Chipscreen Biosciences Secures Macao Market Approval for Bilessglu (Chiglitazar), Novel PPAR Pan-Agonist for Type 2 Diabetes

Fineline Cube May 15, 2026

Chipscreen Biosciences Co., Ltd. (SHA: 688321) announced it has received marketing clearance from the Pharmaceutical...

Company Deals

Hybio Pharmaceutical Licenses GLP-1 Copycats to MCG Pharma for Exclusive Turkish Commercialization

Fineline Cube May 12, 2026

Hybio Pharmaceutical Co., Ltd. (SHE: 300199) announced a strategic licensing agreement with MCG Pharma, the...

Company Drug

Jiangsu Lianhuan Pharma Reports Positive Phase III Results for LH-1801 SGLT-2 Inhibitor in Type 2 Diabetes Treatment

Fineline Cube May 8, 2026

Jiangsu Lianhuan Pharmaceutical Co., Ltd. (SHA: 600513) announced successful unblinding of two pivotal Phase III...

Diabetes

NMPA Accepts Hengrui’s New Drug Application for Ribupatide Injection – Dual GLP‑1/GIP Receptor Agonist Nears Approval for Type 2 Diabetes in China

GanLee’s GZC8072 Wins NMPA IND Approval for Once‑Weekly Oral Type 2 Diabetes Candidate

Hengrui Pharmaceuticals’ Oral GLP‑1R Agonist HRS‑7535 NDA Accepted by NMPA for Type 2 Diabetes, Joining China’s Incretin Race

Hengrui Pharmaceuticals Wins NMPA Clearance for Phase II Trial of HRS‑4729, a Triple‑Agonist Peptide Drug for Type 2 Diabetes

Novo Nordisk Sues Eli Lilly Over Alleged False Advertising of Zepbound and Mounjaro in GLP-1 Market

Mabwell Bioscience Secures NMPA Approval for 9MW5211 Antibody in Type 1 Diabetes, Expanding Autoimmune Pipeline

Hybio Pharma’s Generic Tirzepatide ANDA Accepted by FDA – First-to-File Challenger Targets $20B+ Dual GLP-1/GIP Agonist Franchise with Paragraph IV Certification

Hua Medicine Completes Greater China Rollout as Dorzagliatin Gains Macau Approval – First-in-Class Glucokinase Activator Now Available Across All Chinese Territories

MacroGenics Secures $24.5M Milestone from Sanofi Following FDA Approval Expansion for Tzield in Type 1 Diabetes

Gan & Lee Pharmaceuticals Secures UAE Approval for Insulin Glargine Prefilled Pen, Expanding Global Diabetes Portfolio

CSPC Pharmaceutical’s Efmedaglutide Alfa GLP-1 Therapy Accepted for NMPA Review in Type 2 Diabetes Indication

Sanofi’s Tzield Receives FDA Approval to Preserve Insulin Production in Recently Diagnosed Type 1 Diabetes

PegBio Receives $7.8M Milestone Payment from Tenry Pharma for Paidakang GLP-1 Agonist – Chinese Biotech Secures First Commercial Revenue from Type 2 Diabetes Asset

Novo Nordisk’s CagriSema Fixed-Dose Combination Delivers Superior HbA1c and Weight Loss in Phase 3 REIMAGINE Trials – Amylin/GLP-1 Dual Therapy Outperforms Semaglutide Monotherapy

Shandong Boan Biotech Licenses BA5101 Dulaglutide Biosimilar for US Market – First Global Copycat of Trulicity

Hanmi Pharm Secures $1.26 Billion Deal with Eli Lilly for GLP-2 Analog Sonefpeglutide in Global Licensing Agreement

Hengrui Pharmaceuticals and Kailera Therapeutics Report Strong Phase III Results for Oral GLP-1 Agonist HRS-7535 in Type 2 Diabetes

Chipscreen Biosciences Secures Macao Market Approval for Bilessglu (Chiglitazar), Novel PPAR Pan-Agonist for Type 2 Diabetes

Hybio Pharmaceutical Licenses GLP-1 Copycats to MCG Pharma for Exclusive Turkish Commercialization

Jiangsu Lianhuan Pharma Reports Positive Phase III Results for LH-1801 SGLT-2 Inhibitor in Type 2 Diabetes Treatment

You Missed

Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption

BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis

Walvax’s Third‑Generation COVID‑19 mRNA Vaccine Wins NMPA Approval – JN.1‑Based Shot Clears Regulatory Bar for Adults in China

China’s Seventh National VBP Round for Medical Consumables Concludes in Tianjin – 517 Digestive Intervention Products Selected Across 23 Categories